Dragon Pharma Survodutide 10 mg - GLP-1 Glucagon Agonist Vial

Dragon Pharma Survodutide 10 mg - GLP-1 and Glucagon Dual Agonist

Dragon Pharma Survodutide 10 mg supplies the dual GLP-1 and glucagon receptor agonist peptide as a lyophilised 10 mg research vial. The peptide is investigated for metabolic disease and has no approved label in this form, so it is a laboratory material rather than a medicine. Survodutide for sale from a GMP manufacturer with independent batch testing and a Certificate of Analysis on file.

• Survodutide 10 mg per lyophilised research vial
• Dual GLP-1 and glucagon receptor agonist
• Reference plasma half-life about 6 days with high albumin binding
• GMP-manufactured, HPLC-verified, COA on file per batch

How Survodutide Works

Survodutide activates the GLP-1 receptor and the glucagon receptor at the same time. The GLP-1 arm slows gastric emptying and raises satiety signalling, exactly as Semaglutide does, while the glucagon arm increases energy expenditure and shifts hepatic fuel handling. That combination is why the peptide is grouped with the triple agonist Retatrutide rather than with single-incretin products: both add a non-incretin receptor to the appetite signal. Albumin binding above 99% keeps the peptide in circulation for about six days.

Research Amounts and Handling

No dose is approved for this vial, so every figure is research practice. Research-phase material describes weekly subcutaneous steps of 0.3 to 0.6 mg at the low end, 2.4 to 4.8 mg in the middle, and up to 6.0 mg per week at the top, with step increases no faster than monthly. The six-day half-life means accumulation builds over weeks, so laboratory planning is about steady state rather than a single dose. Reconstitute the 10 mg vial with bacteriostatic water: 2 ml gives 5 mg per ml and 5 ml gives 2 mg per ml. Store the powder at 2-8 C away from light and the solution refrigerated.

Quality & Authenticity

Every batch is produced under GMP conditions and checked by independent HPLC, with the Certificate of Analysis held for the batch. Nausea, vomiting, diarrhoea and constipation dominate the reported profile, appetite can fall to food aversion, and gallbladder events and pancreatitis are class warnings for incretin peptides. Mazdutide is a GLP-1 and glucagon dual agonist from the same research family, while Tirzepatide uses a different receptor pair.

For laboratory research only. Consult a healthcare professional before use.

Consult a healthcare professional before any cycle. Doses are common community protocols.